New York, New York, USA, November 16, 2026
DarioHealth Corp. has presented new research at ISPOR Europe 2026 highlighting a biometric-driven methodology for estimating healthcare cost savings and return on investment (ROI) from digital chronic disease management programmes. The research introduces a model that translates improvements in measurable health indicators, including blood pressure, blood glucose, and body weight, into projected reductions in medical expenditure. The approach is designed to help employers, health plans, and healthcare organisations assess the potential economic value of digital health interventions without waiting for medical claims data, which can take several months to become available or may not be accessible. Presented by Yifat Hershcovitz, Ph.D., Vice President of Clinical and Scientific Affairs at DarioHealth, the research addresses a common challenge in digital healthcare: connecting measurable changes in patient health with financial outcomes. The presentation took place during ISPOR Europe 2026, held from November 8 to 11 in Vienna, Austria. According to DarioHealth, the methodology is intended to provide a transparent and replicable way to estimate potential savings and support healthcare purchasers in evaluating digital chronic disease management programmes.
Biometric Data Provides an Alternative to Claims-Based Analysis
The research, titled “Estimating Individual-Level Medical Cost Savings from Digital Chronic Disease Management: A Biometric-to-PMPM Proxy Methodology,” describes a retrospective model that converts observed biometric improvements into estimated healthcare expenditure reductions. The methodology uses changes in blood pressure, blood glucose, and body weight as measurable indicators of health improvement. These changes are then linked to published medical cost data to calculate projected savings. The model uses a per-member-per-month (PMPM) framework, a commonly used healthcare financial measure that estimates expenditure for each enrolled member over a month. Traditionally, employers and health plans may rely on medical claims data to determine whether a healthcare programme has reduced hospital visits, medical procedures, medication costs, or other healthcare expenditure. However, claims information can be delayed, creating difficulties when organisations need to evaluate programme performance within a specific financial year. DarioHealth’s approach is intended to address this information gap by using available biometric measurements to estimate potential cost reductions earlier. The model does not require organisations to wait for claims data before generating an economic estimate, although its projections should be distinguished from actual, independently verified reductions in healthcare spending.
Digital Chronic Disease Management and Healthcare ROI
DarioHealth’s research focuses on the economic evaluation of digital programmes supporting people with chronic conditions, particularly cardiometabolic health needs such as diabetes, hypertension, and weight management. These conditions can require ongoing monitoring, lifestyle support, clinical interventions, and long-term healthcare expenditure. Digital chronic disease management platforms combine connected devices, personalised engagement, data analysis, and healthcare support to help individuals monitor and manage their health. By measuring changes in relevant biometric indicators, programme providers can assess whether participants are demonstrating improvements during the intervention period. DarioHealth states that its methodology can help translate these changes into estimates that healthcare purchasers can use when assessing the financial value of digital health programmes. The company also highlighted the potential for estimated savings to increase when multiple chronic conditions are addressed within a single programme. This could be relevant to employers and health plans seeking integrated solutions for populations with overlapping health needs. However, the research announcement does not provide specific monetary savings figures, a quantified ROI result, or detailed comparative clinical outcomes. The findings therefore describe an economic estimation methodology, rather than definitive evidence that a particular amount of healthcare expenditure has already been avoided.
Research Supports Evidence-Based Digital Health Evaluation
The presentation adds to DarioHealth’s broader work in AI-powered healthcare technology and personalised chronic disease management. The company’s platform combines connected devices, member engagement, AI-driven insights, and provider-supported clinical care. According to DarioHealth, its technology is supported by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade. The company believes that combining biometric, clinical, and behavioural information can support more personalised interventions and help organisations evaluate programme performance. The newly presented methodology may also support business decisions involving new customer relationships, contract renewals, and expansion into additional conditions and populations. For healthcare purchasers, transparent economic evaluation is important when comparing digital health solutions and deciding how to allocate resources. Nevertheless, the reliability of any projected savings depends on the quality of biometric measurements, the assumptions used to translate health changes into costs, and the suitability of published cost benchmarks for the population being evaluated. Independent validation and comparison with actual claims-based expenditure would strengthen confidence in the model’s estimates. Overall, DarioHealth’s ISPOR Europe 2026 presentation highlights an emerging approach to connecting measurable health improvements with healthcare economics, potentially helping organisations assess digital chronic disease management programmes more efficiently.
Source: DarioHealth press release



